Early antiplatelet for minor stroke following thrombolysis (EAST): Rationale and design

Abstract

Background:

Early neurological deterioration (END) occurs in about 10% of patients after intravenous thrombolysis (IVT) and is related to poor outcome. In theory, early antiplatelet following IVT could reduce END by preventing re-occlusion and stroke progression, but current guidelines recommend starting antiplatelet treatment at 24 h after IVT due to concerns about hemorrhagic transformation. Given higher risk of hemorrhagic transformation in severe stroke, we hypothesized that minor stroke patients following IVT can safely benefit from early antiplatelet treatment.

Aims:

To explore the efficacy and safety of early antiplatelet in minor stroke patients after IVT.

Sample size estimates:

A maximum of 1022 patients are required to test the superiority hypothesis with 80% power according to a two-side 0.05 level of significance, stratified by age, gender, history of stroke or transient ischemic attack, history of hypertension, history of diabetes mellitus, systolic blood pressure at admission, time from IVT to treatment, thrombolysis drug, stroke territory, and stroke etiology.

Design:

Early antiplatelet for minor stroke following thrombolysis is a prospective, double-blinded, multicenter, randomized and placebo-controlled trial. Minor stroke patients within 6 h following IVT are randomly assigned into experimental group and control group with the ratio of 1:1. The experimental group is orally administered with 300 mg clopidogrel and 100 mg aspirin, and control group with placebo. Subsequently, both groups received guideline-based antithrombotic treatment from 24 h after IVT to 90 days.

Outcome:

The primary efficacy endpoint is excellent functional outcome, defined as the modified Rankin Scale 0–1 at 90 days after randomization, while primary safety endpoint is symptomatic intracerebral hemorrhage, defined as National Institutes of Health Stroke Scale score increase ⩾ 4 caused by intracranial hemorrhage within 36 h after randomization.

Conclusions:

The results of EAST will provide us powerful early antiplatelet evidence for minor stroke population following intravenous thrombolysis in clinical practice.

Keywords

Acute stroke therapy antiplatelet therapy thrombolysis treatment protocols ischaemic stroke

Get full access to this article

View all access options for this article.

References

Powers

Rabinstein

Ackerson

, et al Guidelines for the early management of patients with acute ischemic stroke—2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2019; 50: e344–e418.

Neurology Branch of Chinese Medical Association. Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2014. Chin J Neurol [Chinese] 2015; 48: 246–257.

National Institute of Neurological Disorders Stroke rt-PA and Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–1587.

Pancioli

Broderick

Brott

, et al The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke 2008; 39: 3268–3276.

Adeoye

Sucharew

Khoury

, et al Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis. Stroke 2015; 46: 461–464.

Adeoye

Sucharew

Khoury

, et al Combined approach to lysis utilizing eptifibatide and recombinant tissue-type plasminogen activator in acute ischemic stroke-full dose regimen stroke trial. Stroke 2015; 46: 2529–2533.

Lin

Zhang

, et al Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients. Stroke 2016; 47: 2649–2651.

Liu

Shi

Sun

, et al Efficacy of tirofiban administered at different time points after intravenous thrombolytic therapy with alteplase in patients with acute ischemic stroke. J Stroke Cerebrovasc Dis 2019; 28: 1126–1132.

Zinkstok

Roos

and ARTIS investigators. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet 2012; 380: 731–737.

10.

Emberson

Lees

Lyden

, et al Stroke Thrombolysis Trialists’ Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014; 384: 1929–1935.

11.

Wang

, et al INTRECIS Investigators. Effectiveness of intravenous r-tPA versus UK for acute ischaemic stroke: a nationwide prospective Chinese registry study. Stroke Vasc Neurol 2021; 6: 603–609.

12.

Saber

Khatibi

Szeder

, et al Reperfusion therapy frequency and outcomes in mild ischemic stroke in the United States. Stroke 2020; 51: 3241–3249.

13.

Griessenauer

Medin

Maingard

, et al Endovascular mechanical thrombectomy in large-vessel occlusion ischemic stroke presenting with low National Institutes of Health Stroke Scale: systematic review and meta-analysis. World Neurosurg 2018; 110: 263–269.

14.

Seners

Ben Hassen

Lapergue

, et al Prediction of early neurological deterioration in individuals with minor stroke and large vessel occlusion intended for intravenous thrombolysis alone. JAMA Neurol 2021; 78: 321–328.

15.

Khatri

Wechsler

Broderick

JP.

Intracranial hemorrhage associated with revascularization therapies. Stroke 2007; 38: 431–440.

16.

Wang

Zhao

, et al Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369: 11–19.

17.

Johnston

Easton

Farrant

, et al Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018; 379: 215–225.

18.

Anderson

Robinson

Lindley

, et al Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke. N Engl J Med 2016; 374: 2313–2323.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB